159 filings
Page 3 of 8
8-K
p9ok1 v4zu3i
3 Jun 22
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
mcbg1z546ri37
5 May 22
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
4:03pm
DEFA14A
zn9 uw8cjwudnheon9
19 Apr 22
Additional proxy soliciting materials
4:03pm
8-K
ebghoc7sd c3v1ycqy
16 Mar 22
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial
4:20pm
8-K
elatwnk8 xkwap3ucdn
28 Feb 22
Entry into a Material Definitive Agreement
5:27pm
S-3ASR
1msbqiuj5bn
28 Feb 22
Automatic shelf registration
5:26pm
S-8
cg8l91oqhtyiz1o pb
28 Feb 22
Registration of securities for employees
4:22pm
8-K
dyq 58ltv761c6l0
28 Feb 22
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
4:04pm
8-K
9n4ro
14 Feb 22
Regulation FD Disclosure
6:29am
8-K
h4oekxc 54
10 Feb 22
Other Events
9:01am
8-K
fs9wkcoeqvqscd vyz
7 Feb 22
Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors
4:03pm
8-K
7i15q03n 7gk
10 Jan 22
Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022
9:06am
8-K
u2jl7rl
17 Nov 21
Regulation FD Disclosure
9:03am
8-K
v456ui0dc
4 Nov 21
Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
4:04pm
8-K
5zc0k
4 Aug 21
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
4:03pm